デフォルト表紙
市場調査レポート
商品コード
922066

世界の肺動脈性肺高血圧症(PAH)市場:成長、動向、および予測

Pulmonary Arterial Hypertension Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 111 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.65円
世界の肺動脈性肺高血圧症(PAH)市場:成長、動向、および予測
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 111 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の肺動脈性肺高血圧症(PAH)市場について調査しており、市場機会や動向、成長および阻害要因、薬剤クラス・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 肺動脈高血圧症の負担増大
    • オーファンドラッグ(希少疾病用医薬品)の開発に対する政府および民間の支援
  • 市場阻害要因
    • 薬物分子の特許失効
    • 薬物に関連する副作用
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 薬剤クラス別
    • プロスタサイクリン・プロスタサイクリン類似体
    • カルシウム拮抗薬
    • ホスホジエステラーゼ5(PDE-5)
    • エンドセリン受容体拮抗薬(ERA)
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Arena Pharmaceuticals
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)
    • Merck & Co. Inc.
    • Novartis International AG
    • Pfizer, Inc.
    • United Therapeutics Corporation

第7章 市場機会および今後の動向

目次
Product Code: 67621

Pulmonary arterial hypertension is a group of rare and life-threatening diseases that leads to increased pulmonary arterial pressure and localized hypertension, which can result in heart failure. The increasing prevalence of pulmonary arterial hypertension, government support for the development of orphan drugs and the growing geriatric population are the main factors that are boosting the growth of the pulmonary arterial hypertension market. According to the World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. The symptoms of Pulmonary arterial hypertension include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting. The increase in the number of geriatrics leads to consequences which is several cases includes complications related to pulmonary arterial hypertensions. The technological advancements are also steadily focusing upon identification of new molecular pathways which contributes to developement of better treatments possible over the forecast period. All these factors boost the growth of the market.

However, patent expiration of drug molecule and side effects associated with the drugs is expected to impede the growth of the global market in the forecast period.

Key Market Trends

Prostacyclin and Prostacyclin Analogs Segment is Expected to Observe Better Growth Over the Forecast Period

Based on drug class, the market is segmented into Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA) and Others. Prostacyclin and Prostacyclin Analogs segment is expected to show better growth in the forecast period, owing to the high sales of these drugs and rising number of drug approvals. According to the National Organization for Rare Disorders, new cases are estimated to occur in one to two individuals per million each year in the U.S. The incidence is estimated to be similar in Europe. Pulmonary hypertension occurs at all ages, and the incidence of it increases with age. The high growth is attributed to changing lifestyle, in terms of lack of physical activity and increased consumption of alcohol and tobacco, which increases the chances of developing hypertension and high blood pressure. The increased blood pressure in turn, gives rise to various diseases such as stroke and heart attacks. Hypertension is considered as a variable health risk and is often related to high morbidity and mortality.

North America is Estimated to Lead the Pulmonary Arterial Hypertension Market

North America leads the Pulmonary Arterial Hypertension (PAH) Market, owing to the presence of the highly developed healthcare sector, along with the rising prevalence of infectious and chronic diseases. About 200,000 hospitalizations occur annually in the United States with pulmonary hypertension. Moreover, increased awareness, high diagnosis rate, and supportive government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 will support the market growth. There are certain useful developments shown by the companies and supported by the government related to pulmonary arterial hypertension activities. In 2019, Bayer announced recipients of the inaugural Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary, which is expected to drive the pulmonary arterial hypertension market in the forecast period.

Competitive Landscape

The leading players in the global market for Pulmonary Arterial Hypertension are - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Pulmonary Arterial Hypertension
    • 4.2.2 Government and Private Support for the Development of Orphan Drugs
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiration of Drug Molecule
    • 4.3.2 Side Effects Associated with the Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Prostacyclin and Prostacyclin Analogs
    • 5.1.2 Calcium Channel Blockers
    • 5.1.3 Phosphodiesterase 5 (PDE-5)
    • 5.1.4 Endothelin Receptor Antagonists (ERA)
    • 5.1.5 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arena Pharmaceuticals
    • 6.1.2 Bayer AG
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Gilead Sciences, Inc.
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Novartis International AG
    • 6.1.9 Pfizer, Inc.
    • 6.1.10 United Therapeutics Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS